Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762.The $9 million market cap biotech is surging with a session volume of 5.82 million compared to the average volume of 412.49 thousand, according to Benzinga Pro data.Safety Data UpdateThe Safety Monitoring Committee concluded its review of the trial, reporting no serious adverse events or dose-limiting toxicities across all five dose esca ...